Bioventus Inc. (NASDAQ:BVS) Stock Has Average Price Target of $16.80 According to Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.80.

BVS has been the topic of several recent research reports. Barrington Research set a $18.00 price target on Bioventus in a research report on Thursday, August 6th. Canaccord Genuity Group increased their price objective on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Craig Hallum reiterated a “buy” rating and issued a $18.00 target price on shares of Bioventus in a research note on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price target on shares of Bioventus in a research note on Monday, August 17th.

Hedge Funds Weigh In On Bioventus

Several institutional investors and hedge funds have recently added to or reduced their stakes in BVS. Hillsdale Investment Management Inc. increased its position in Bioventus by 148.7% during the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock worth $6,128,000 after purchasing an additional 401,230 shares during the period. Engine Capital Management LP acquired a new stake in shares of Bioventus in the 1st quarter valued at approximately $2,876,000. Inspire Investing LLC acquired a new stake in shares of Bioventus in the 1st quarter valued at approximately $1,670,000. Sei Investments Co. lifted its holdings in shares of Bioventus by 160.7% in the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after buying an additional 178,539 shares during the period. Finally, Globeflex Capital L P purchased a new stake in shares of Bioventus in the second quarter valued at approximately $1,566,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Price Performance

BVS stock opened at $15.04 on Friday. The company has a market capitalization of $1.26 billion, a P/E ratio of 19.53, a PEG ratio of 1.81 and a beta of 0.64. Bioventus has a twelve month low of $6.47 and a twelve month high of $15.89. The business has a 50 day simple moving average of $13.68 and a 200-day simple moving average of $11.66. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. The business had revenue of $153.21 million for the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities analysts anticipate that Bioventus will post 0.79 EPS for the current year.

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.